
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo Inc has demonstrated a consistent growth trajectory in its reimbursement pipeline, increasing from 1,389 units in Q4 to 1,669 units in the latest quarter, highlighting an upward trend in demand for its myoelectric orthotics. The company is strategically redirecting its focus towards the expansive Medicare market, which is expected to significantly bolster revenue, particularly as O&P providers are projected to contribute approximately 22% of total revenue in 2024. Furthermore, the recent favorable ruling from CMS to include the MyoPro under Medicare Part B benefits substantially broadens Myomo's market potential, positioning the company for enhanced financial performance moving forward.
Bears say
Myomo Inc. has significantly lowered its 2025 revenue guidance from a range of $50–53 million to $40–42 million, indicating potential operational challenges ahead. Additionally, a decline in the backlog of insurance-authorized devices, dropping from 272 in Q4 to 208, reflects a concerning trend in the company's sales pipeline and demand for their products. The company's recent marketing effectiveness and lead conversion rates have underperformed expectations, suggesting a weakened competitive position and raising concerns regarding future revenue growth.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares